Advertisement
Advertisement
ADPT
Adaptive Biotechnologies Corporation Common Stock
17.53
USDSponsored
+0.75
+4.47%
Jun 18, 16:00 UTC -4
Closed
After-Market
17.70
+0.17
+0.96%
ADPT Earnings Reports
Positive Surprise Ratio
ADPT beat 23 of 28 last estimates.
82%
Next Report
Date of Next Report
Aug 03, 2026
Estimate for Q2 26 (Revenue/ EPS)
$67.42M
/-$0.13
Implied change from Q1 26 (Revenue/ EPS)
-4.87%
/+8.33%
Implied change from Q2 25 (Revenue/ EPS)
+14.51%
/-23.53%
Adaptive Biotechnologies Corporation Common Stock earnings per share and revenue
On May 05, 2026, ADPT reported earnings of -0.12 USD per share (EPS) for Q1 26, beating the estimate of -0.16 USD, resulting in a 26.47% surprise. Revenue reached 70.87 million, compared to an expected 62.07 million, with a 14.19% difference. The market reacted with a +4.72% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 10 analysts forecast an EPS of -0.13 USD, with revenue projected to reach 67.42 million USD, implying an increase of 8.33% EPS, and decrease of -4.87% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
enGene Therapeutics Inc. Common Stock
Report Date
Jun 15, 2026 For Q2 26
Estimate
-$0.47
Actual
-$0.43
Surprise
+10.32%
Greenwich LifeSciences, Inc.
Report Date
Jun 04, 2026 For Q1 26
Estimate
-$0.33
Actual
-$0.39
Surprise
-15.86%
Prenetics Global Limited Class A Ordinary Share
Report Date
Jun 10, 2026 For Q1 26
Estimate
-$1.10
Actual
-$1.61
Surprise
-45.36%
Anixa Biosciences, Inc.
Report Date
Jun 10, 2026 For Q2 26
Estimate
-$0.08
Actual
-$0.07
Surprise
+21.61%
Vistagen Therapeutics, Inc. Common Stock
Report Date
Jun 15, 2026 For Q4 26
Estimate
-$0.34
Actual
-$0.37
Surprise
-7.75%
FAQ
What were Adaptive Biotechnologies Corporation Common Stock's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Adaptive Biotechnologies Corporation Common Stock reported EPS of -$0.12, beating estimates by 26.47%, and revenue of $70.87M, 14.19% above expectations.
How did the market react to Adaptive Biotechnologies Corporation Common Stock's Q1 2026 earnings?
The stock price moved up 4.72%, changed from $13.78 before the earnings release to $14.43 the day after.
When is Adaptive Biotechnologies Corporation Common Stock expected to report next?
The next earning report is scheduled for Aug 03, 2026.
What are the forecasts for Adaptive Biotechnologies Corporation Common Stock's next earnings report?
Based on 10
analysts, Adaptive Biotechnologies Corporation Common Stock is expected to report EPS of -$0.13 and revenue of $67.42M for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement